How Strong Were Eli Lilly Q1 2026 Earnings?
I break down Eli Lilly and Company Q1 2026 earnings, including the 56 percent revenue jump to $19.8 billion, the $8.55 adjusted EPS, the rise of Zepbound and Mounjaro, the launch of the Foundayo oral GLP-1 pill, and the raised $82 to $85 billion full year guidance.
Quick Answer
Eli Lilly and Company reported Q1 2026 worldwide revenue of $19.8 billion, up 56 percent year over year and well ahead of the $17.62 billion analyst consensus. Non-GAAP adjusted EPS came in at $8.55, beating the $6.66 expectation by 28 percent, and shares jumped more than 10 percent on the day.
Growth was led by Mounjaro and Zepbound, a 60.1 percent U.S. GLP-1 market share, and the April 2026 FDA approval of Foundayo, the first true oral GLP-1 pill. Lilly raised full year 2026 guidance to $82.0 to $85.0 billion in revenue and $35.50 to $37.00 in adjusted EPS.
Crushing Wall Street Estimates
When a company the size of Eli Lilly posts growth that looks like a startup, markets pay attention. Q1 2026 was historic for the Indianapolis based maker of Mounjaro, Zepbound, Trulicity, Verzenio, and Taltz.
Revenue and Earnings
Worldwide revenue hit $19.8 billion, a 56 percent jump from Q1 2025. That comfortably beat the $17.62 billion analyst consensus. Non-GAAP adjusted EPS landed at $8.55, 28 percent above the $6.66 estimate. Net income climbed to $7.4 billion, up 168 percent. The stock surged more than 10 percent on the print, reinforcing Lilly as one of the most valuable healthcare names on the planet.
Volume vs. Price
Underneath the 56 percent revenue line, the mix is even more interesting. Global prescription volume rose 65 percent. Realized prices fell 13 percent, mostly from cash pay discount programs and aggressive contracting to win preferred formulary status against Novo Nordisk. Volume crushed price, which is the cleanest sign of true demand.
Mounjaro and Zepbound Dominate
The Key Products portfolio generated $13.4 billion in Q1, anchored by the GLP-1 and GIP dual agonists.
Zepbound
Zepbound, the chronic weight management brand, did $4.16 billion in U.S. revenue alone, up roughly 80 percent year over year. According to Q1 share data, Lilly now holds a 60.1 percent share of the U.S. GLP-1 market, with Novo Nordisk at 39.4 percent.
Mounjaro
Mounjaro continues to anchor Type 2 diabetes. Together the two drugs drove a 49 percent jump in U.S. branded prescriptions. CEO David A. Ricks noted that international markets are scaling fast as supply normalizes and more regulators clear the dual agonists.
The Foundayo Oral GLP-1 Approval
The biggest structural news in Q1 was not in the income statement. In April 2026, the FDA approved Foundayo, the first true oral GLP-1 pill from Lilly.
Why It Matters
Until Foundayo, GLP-1 therapy meant weekly subcutaneous injections. Effective, but a hard ask for needle averse patients. Foundayo can be taken at any time of day, with no fasting and no water restrictions, removing the biggest practical friction in oral peptides.
Early Launch
Ricks said that within weeks of the Q2 launch, more than 20,000 patients had already started Foundayo, with daily new starts running above 1,000. Phase 3 data published in The Lancet showed Foundayo delivered superior glycemic control versus oral semaglutide. That opens a clean lane into patients who never wanted to inject.
Strategic Acquisitions and Pipeline
Lilly is reinvesting the cash flow rather than coasting. The company recognized $584 million in acquired in process research and development charges in Q1, tied to four pipeline deals across cell therapy and specialty care.
- Orna Therapeutics
- Centessa Pharmaceuticals plc
- Kelonia Therapeutics
- Ajax Therapeutics
The company also reported encouraging data for a Taltz plus Zepbound combination in adults with both psoriatic arthritis and obesity, a real signal that Lilly is leaning into multi indication chronic disease.
Raised 2026 Guidance
The clearest signal of internal confidence is the forward outlook. On the back of the Q1 print, Lilly raised full year revenue guidance by $2 billion.
| Metric | Prior 2026 Guide | New 2026 Guide |
|---|---|---|
| Revenue | $80.0 to $83.0 billion | $82.0 to $85.0 billion |
| Non-GAAP EPS | $34.50 to $36.00 | $35.50 to $37.00 |
That bake reflects continued Mounjaro and Zepbound scaling, the Foundayo ramp, and expected expansion of Medicare obesity coverage later in 2026. Ricks estimates global GLP-1 use can move from roughly 20 million patients at the end of 2025 to around 30 million by the end of 2026.
Risks to Watch
The bull case is loud, but the risk list is real. Federal drug pricing negotiations remain a structural pressure. Net realized prices are still falling under fierce competition. Manufacturing capacity has to keep scaling globally to meet demand, and any miss there hurts the top line directly.
Frequently Asked Questions
What was Eli Lilly Q1 2026 revenue?
$19.8 billion worldwide, up 56 percent year over year.
What was Eli Lilly Q1 2026 adjusted EPS?
$8.55 on a non-GAAP basis, 28 percent above the $6.66 consensus.
What is Foundayo?
Foundayo is Lilly\u2019s FDA approved oral GLP-1 pill, taken any time of day with no fasting or water restrictions.
What is the new 2026 guidance?
$82.0 to $85.0 billion in revenue and $35.50 to $37.00 in non-GAAP adjusted EPS.